Charles Schwab Investment Management Inc. Boosts Stake in X4 Pharmaceuticals, Inc. $XFOR

Charles Schwab Investment Management Inc. raised its holdings in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 9.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 481,528 shares of the company’s stock after purchasing an additional 43,320 shares during the period. Charles Schwab Investment Management Inc. owned 8.32% of X4 Pharmaceuticals worth $114,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Northern Trust Corp lifted its position in X4 Pharmaceuticals by 2.9% in the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock valued at $996,000 after acquiring an additional 37,940 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in X4 Pharmaceuticals by 4.0% in the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after purchasing an additional 24,948 shares during the period. Jane Street Group LLC lifted its stake in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock valued at $428,000 after buying an additional 335,036 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of X4 Pharmaceuticals by 559.6% during the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock valued at $195,000 after buying an additional 227,051 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after buying an additional 22,485 shares in the last quarter. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Stock Up 16.7%

Shares of NASDAQ XFOR opened at $3.64 on Friday. The company has a 50-day moving average of $2.30 and a 200 day moving average of $4.87. X4 Pharmaceuticals, Inc. has a 12-month low of $1.35 and a 12-month high of $26.83. The company has a current ratio of 3.19, a quick ratio of 3.05 and a debt-to-equity ratio of 19.10. The stock has a market cap of $41.53 million, a PE ratio of -0.25 and a beta of 0.61.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Friday, August 8th. The company reported ($3.47) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $1.06. X4 Pharmaceuticals had a negative net margin of 311.15% and a negative return on equity of 375.31%. The business had revenue of $1.97 million during the quarter, compared to analysts’ expectations of $1.62 million. As a group, sell-side analysts predict that X4 Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Analysts Set New Price Targets

XFOR has been the subject of a number of research analyst reports. HC Wainwright set a $3.50 price objective on X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 13th. Stifel Nicolaus decreased their price objective on shares of X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, August 29th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, X4 Pharmaceuticals presently has an average rating of “Buy” and an average target price of $34.17.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.